25 Ridge Boulevard
Rye Brook, NY 10573
Biotech Communications offers short, highly focused consultations to development-stage biotech companies seeking to expand their communications to new and existing stakeholders/audiences. Our typical consultation totals less than 10 hours spread over the course of three months, and focuses on helping companies to:
1. Develop a unique and effective voice for communicating with audiences that range from researchers, physicians and patients – to reports, regulators, and of course, investors
2. Establish effective processes for message development and issues management
3. Decide which communications position(s) to create internally
4. Select and manage external resources (e.g., PR, IR and branding/communications firms) cost-effectively
Members of BioCT are entitled to a 75-minute initial consultation without charge or obligation.
All consultations are provided by Irving Adler, who retired as Alexion Pharmaceuticals’ vice president of global corporate communications in 2016 after 30 years in communications. Irving led Alexion’s corporate and investor communications as the company grew from its Connecticut base into a global organization serving patients in 50 countries. Previously, Irving advised healthcare firms including Pfizer, Schering-Plough, The American Red Cross, Baxter International and The Mount Sinai Medical Center, as well as the United Nations, IBM, Verizon, PriceWaterhouseCoopers and the City of New York.